A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
A study of tolododekin alfa (also known as ANK-101) administered in combination with an
anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1)
antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Cohort ...
Age: 18 years - 66+
Gender: All
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in
deciding which study treatment patients are assigned. Patient cancer tissue samples are
obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid
(D...
Age: 18 years - 66+
Gender: All
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in
deciding which study treatment patients are assigned. Patient cancer tissue samples are
obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid
(D...
Age: 18 years - 66+
Gender: All
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin
(TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that
accumulates in different organs in the body and can cause damage to the organ. There are
two way...
Age: 18 - 75 years
Gender: All
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin
(TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that
accumulates in different organs in the body and can cause damage to the organ. There are
two way...
Age: 18 - 75 years
Gender: All
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the
incidence of serious heart-related complications or prevent the worsening of kidney
function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and
Atheroscl...
Age: 45 years - 66+
Gender: All
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the
incidence of serious heart-related complications or prevent the worsening of kidney
function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and
Atheroscl...
Age: 45 years - 66+
Gender: All
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency (OTC-HOPE)
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an
inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for
detoxification of ammonia. Individuals with OTC deficiency can build-up excess levels of
...
Age: 24 hours - 7 months
Gender: Male
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an
inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for
detoxification of ammonia. Individuals with OTC deficiency can build-up excess levels of
...
Age: 24 hours - 7 months
Gender: Male
IMPRoving Outcomes in Vascular DisEase - Aortic Dissection
The goal of this clinical trial is to determine whether an upfront invasive strategy of
TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause
death or major aortic complications compared to an upfront conservative strategy of
medical ...
Age: 21 years - 66+
Gender: All
IMPRoving Outcomes in Vascular DisEase - Aortic Dissection
The goal of this clinical trial is to determine whether an upfront invasive strategy of
TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause
death or major aortic complications compared to an upfront conservative strategy of
medical ...
Age: 21 years - 66+
Gender: All
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical
recurrence (BCR) of prostate cancer.
BCR means that in men who had prostate cancer and were treated by either surgery and/ or
radiation therapy, the blood level of a specific protein ...
Age: 18 years - 66+
Gender: Male
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical
recurrence (BCR) of prostate cancer.
BCR means that in men who had prostate cancer and were treated by either surgery and/ or
radiation therapy, the blood level of a specific protein ...
Age: 18 years - 66+
Gender: Male
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in
combination with talquetamab or teclistamab, and to characterize the safety and
tolerability of talquetamab or teclistamab when administered in combination with a PD-1
inhibitor.
Age: 18 years - 66+
Gender: All
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death.
Age: 30 years - 66+
Gender: All
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death.
Age: 30 years - 66+
Gender: All
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
There are many available treatments for pulmonary embolism (PE), but the best treatment
for this condition is not known. The HI-PEITHO study will compare two treatment options
that are both available on the market for the treatment of PE.
Patients will be randomize...
Age: 18 - 80 years
Gender: All
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
There are many available treatments for pulmonary embolism (PE), but the best treatment for
this condition is not known. The HI-PEITHO study will compare two treatment options that are
both available on the market for the treatment of PE.
Patients will be random...
Age: 18 - 80 years
Gender: All
Precision-Based Genomics in Prostate Cancer
Background:
Prostate cancer is the most common cancer and the second leading cause of death in males
in the United States. Researchers want to find additional gene mutations that may
increase a man s risk for prostate cancer and may affect how aggressive the diseas...
Age: 18 years - 66+
Gender: Male